Lancet Diabetes Endocrinol: The effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes

Proteinuria and kidney failure in patients with chronic kidney disease, heart vascular events a recognized risk markers
.

Various drug interventions, including renin-angiotensin system inhibitors, SGLT2 inhibitors and glucagon-like peptide 1 receptor agonists, can reduce proteinuria

Proteinuria and kidney failure in patients with chronic kidney disease, heart vascular events a recognized risk markers

SGLT2 inhibitors were originally developed as oral hypoglycemic agents for patients with type 2 diabetes and are not recommended for patients with chronic kidney disease because it is estimated that patients with low glomerular filtration rate (EGFR) have lower blood glucose efficiency

Recently, researchers have evaluated the effect of dapagliflozin on proteinuria in patients with chronic kidney disease with and without type 2 diabetes in the dapagliflozin and prevention of adverse outcomes of chronic kidney disease (DAPA-CKD) trial

DAPA-CKD is a multicenter, double-blind, placebo-controlled randomized trial conducted in 386 locations in 21 countries
.

If the patient has chronic kidney disease, it is defined as the estimated glomerular filtration rate (eGFR) between 25 ml/min per 1.

DAPA-CKD is a multicenter, double-blind, placebo-controlled randomized trial conducted in 386 locations in 21 countries

According to the quarantined fixed randomization schedule, participants were randomly assigned to reach Gligliflozin 10 mg (AstraZeneca; Gothenburg, Sweden), once a day or matching placebo, using a balance weight to ensure a ratio of approximately 1:1

The regression of the UACR stage is defined as the transition from macroalbuminuria (≥300 mg/g) to microalbuminuria or normal albuminuria (<300 mg/g), the progression of the UACR stage (defined as the progression from less than 3000 mg) /g transition to 3000 mg/g or higher) is an additional discrete endpoint

• During the period from February 2, 2017 to April 3, 2020, 4304 patients were recruited and randomly assigned to the parifluzine group (n=2152) or placebo group (n=2152)
  
  In patients with chronic kidney disease with and without type 2 diabetes, dapagliflozin significantly reduced proteinuria, and the relative reduction was greater in patients with type 2 diabetes
  
  Literature source: Jongs N, Greene T, Chertow GM, et al.
  Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
  Lancet Diabetes Endocrinol.
  2021 ;9(11):755-766.
  doi:10.
  1016/S2213-8587(21)00243-6 Jongs N, Greene T, Chertow GM, et al.
  Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021; 9 (11):.
  .
  .
  755-766 doi: 10.
  1016 / S2213-8587 (21) 00243-6 in this message